Form 4: Director Laurie Smaldone Alsup Acquires TBPH Equity

Theravance Biopharma director Laurie Smaldone Alsup was granted 6,009 ordinary shares and 13,398 stock options as part of annual compensation.

Summary

• Director Laurie Smaldone Alsup acquired 6,009 ordinary shares of Theravance Biopharma (TBPH) on June 12, 2026.
• The director was also granted 13,398 stock options with an exercise price of $16.64.
• The total beneficial ownership for the director following these transactions is 80,989 ordinary shares.
• The stock options vest at a rate of 1/12th per month of continuous service, with remaining unvested shares vesting at the next annual shareholder meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Increased alignment between director interests and shareholder value through equity ownership.
• Standard equity-based compensation structure for board members.

Negatives

• None identified; this is a routine disclosure of director compensation.

Risks

• Market volatility affecting the value of equity-based compensation.
• Potential for future dilution if additional equity grants are issued to board members.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure long-term alignment with company performance and shareholder interests.

Comparison to Industry Standards

• The equity grant structure is consistent with standard corporate governance practices for mid-cap biopharmaceutical companies.
• Vesting schedules tied to continuous service and annual meetings are typical for independent directors in the industry.

Stakeholder Impact

• Positive signal to shareholders regarding director commitment to the company.

Next Steps

• Vesting of stock options on a monthly basis.
• Final vesting of remaining options at the next annual shareholder meeting.

Key Dates

Keywords

Theravance Biopharma, TBPH, Director Compensation, Insider Trading, Form 4, Equity Grant